Erik J. Hicken

Identification of the Clinical Development Candidate <b>MRTX849</b>, a Covalent KRAS^G12C Inhibitor for the Treatment of Cancer

Jay B. Fell, John P. Fischer, Brian R. Baer et al. · Journal of Medicinal Chemistry · 2020 · 594 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Discovery of Tetrahydropyridopyrimidines as Irreversible Covalent Inhibitors of KRAS-G12C with In Vivo Activity

Jay B. Fell, John P. Fischer, Brian R. Baer et al. · ACS Medicinal Chemistry Letters · 2018 · 108 citations · Full text

Pharmacy, Medicinal Chemistry, Oncology +15

Total Synthesis of (+)-Geldanamycin and (−)-<i>o</i>-Quinogeldanamycin:  Asymmetric Glycolate Aldol Reactions and Biological Evaluation

Merritt B. Andrus, Erik L. Meredith, Erik J. Hicken et al. · The Journal of Organic Chemistry · 2003 · 81 citations

Pharmacy, Medicinal Chemistry, Pharmacology +13

Total Synthesis of (+)-Geldanamycin and (−)-<i>o</i>-Quinogeldanamycin with Use of Asymmetric <i>Anti- </i>and <i>Syn</i>-Glycolate Aldol Reactions

Merritt B. Andrus, Erik L. Meredith, Bryon Simmons et al. · Organic Letters · 2002 · 69 citations

Pharmacy, Medicinal Chemistry, Pharmacology +15

Total Synthesis of the Hydroxyketone Kurasoin A Using Asymmetric Phase-Transfer Alkylation

Merritt B. Andrus, Erik J. Hicken, Jeffrey C. Stephens et al. · The Journal of Organic Chemistry · 2006 · 51 citations

Pharmacy, Chemistry, Medicinal Chemistry +10